UnknownNot Applicable

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

China240 participantsStarted 2021-01-08

Plain-language summary

According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction model for TRC.

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Female patients diagnosed with HER2-positive breast cancer treated in our hospital.
. Surgical treatment combined with chemotherapy or radiotherapy was completed according to NCCN guidelines, and trastuzumab standard treatment was received for at least half a year.

Exclusion criteria

. Patients who have not been properly treated with trastuzumab or have been treated for less than half a year;
. Patients who did not receive cardiac function assessment before trastuzumab treatment, during or after treatment;
. Patients whose case data were missing or lost to follow-up.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Cardiac toxicity

Timeframe: 12 months

Cardiac toxicity

Timeframe: 12 months

Cardiac toxicity

Timeframe: 12 months

Cardiac toxicity

Timeframe: 12 months

Trial details

NCT IDNCT04962425

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-06-01

View on ClinicalTrials.gov More Cardiac Toxicity trials

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Female patients diagnosed with HER2-positive breast cancer treated in our hospital.
. Surgical treatment combined with chemotherapy or radiotherapy was completed according to NCCN guidelines, and trastuzumab standard treatment was received for at least half a year.

Exclusion criteria

. Patients who have not been properly treated with trastuzumab or have been treated for less than half a year;
. Patients who did not receive cardiac function assessment before trastuzumab treatment, during or after treatment;
. Patients whose case data were missing or lost to follow-up.